Skip to main
MLYS
MLYS logo

MLYS Stock Forecast & Price Target

MLYS Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Mineralys Therapeutics Inc. is experiencing a positive outlook primarily due to the successful clinical performance of lorundrostat, its oral selective aldosterone synthase inhibitor, which has demonstrated robust blood pressure reductions of 8-12 mmHg in patients with resistant hypertension. The pivotal Launch-HTN Phase 3 trial results indicate significant effectiveness, with a placebo-adjusted reduction of 9.1 mmHg at six weeks and 11.7 mmHg at twelve weeks, combined with a low hyperkalemia rate, highlighting the candidate's favorable safety profile. This strong clinical data supports a strategic opportunity for lorundrostat's daily use in uncontrolled hypertension, positioning Mineralys favorably in the biopharmaceutical market.

Bears say

Mineralys Therapeutics Inc. reported a significant net loss of $48.9 million for the fourth quarter of 2024, translating to a loss of $0.98 per share, and a total net loss of $177.8 million for the full year, at $3.66 per share. Key risks contributing to a negative outlook include the potential failure of lorundrostat to achieve expected peak commercial revenue due to market size, penetration rates, and pricing dynamics. Additionally, the company's ability to secure necessary capital for ongoing operations and the continued development and commercialization of its programs remains uncertain, further compounding the investment risks.

MLYS has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mineralys Therapeutics Inc (MLYS) Forecast

Analysts have given MLYS a Buy based on their latest research and market trends.

According to 8 analysts, MLYS has a Buy consensus rating as of Jul 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mineralys Therapeutics Inc (MLYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.